Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the ...

The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S. bladder cancer patient registry at the 2025 Genitourinary Cancers Symposium ...

Researchers led by the University of Ulsan College of Medicine, Korea, have checked the performance of a noninvasive urinary ...

ALA-guided fluorescence cystoscopy is already widely used, and in March 2005 HAL was approved in Europe for the diagnosis of bladder cancer. The approval process continues in the US. Technical ...

Among patients with suspected MIBC, the incorporation of mpMRI for initial staging prior to transurethral resection of ...

Tommy was diagnosed with bladder cancer just before his 60th birthday. Now, thanks to a Cancer Research UK trial, he’s enjoying playing ...

The bladder cancer market is poised for transformative growth between 2025 and 2035, driven by rising global incidence rates, ...

UGN-102 led to durable responses in low-grade, intermediate-risk bladder cancer, per phase 3 study findings at the 2025 ...

Bladder cancer is one of the most globally prevalent ... However, current diagnostic methods, such as cystoscopy and urine cytology, are invasive, costly, and require specialized personnel.

By test type, the cystoscopy segment accounted for the highest revenue-grossing segment in the global bladder cancer diagnostics market in 2023 owing to the widespread use of cystoscopy as the ...

The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S.